AstraZeneca to publish more detail on US trial after concerns raised

Drugmaker AstraZeneca said it will release further data 'within 48 hours' on US trials of its Covid-19 vaccine, after health officials raised concerns about the initial information disclosed. The company pushed back against a statement from the US National Institute of Allergy and Infectious Diseases (NIAID) which said that 'outdated information' may have been used to conclude that its vaccine was highly effective against Covid. 'We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis,' AstraZeneca said in a statement.